FDA eases compounding policy for hospitalized COVID-19 patients

Apr 16, 2020 - 03:44 PM
FDA

During the COVID-19 emergency, the Food and Drug Administration will not take action in certain circumstances against a registered outsourcing facility for compounding certain drugs to treat hospitalized patients with COVID-19; using a bulk drug substance not on the 503B bulk list; or not meeting current good manufacturing process requirements, the agency announced today.

“Many hospitals are currently experiencing difficulties accessing FDA-approved drug products used for patients with COVID-19,” the agency said. “…[I]n light of unprecedented disruptions to, and demands on, the global pharmaceutical supply chain as a result of the COVID-19 pandemic, and in order to respond to evolving regional conditions, additional flexibility is temporarily needed to ensure that treatment options are available when hospitals are unable to obtain FDA-approved drugs used for hospitalized patients with COVID-19."

Related News Articles

Headline
CDC: Flu activity remains high, COVID-19 increasing while RSV peaks 
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
OSHA ends efforts to establish COVID-19 safety standard 
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
Certain PREP Act liability protections for COVID-19 countermeasures extended through 2029 
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
View the AHA's latest United Against the Flu toolkit celebrating fall
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age 
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
CMS releases final guidance on hospital respiratory data condition of participation reporting requirements 
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…